Silverback Therapeutics, Inc. (SBTX) Prices 11.5M Share IPO at $21/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- Wall Street ends down as oil prices, Treasury yields rise
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil settles up around 4% as Iran's president vows to never surrender
- Wall Street ends down as oil prices, Treasury yields rise
- Anthropic's Claude AI identifies novel enzyme system in DNA search
- AppLovin (APP) on watch amid 3% drop premarket as boutique comments circulate
- Plug Power COO resigns to join another company
- Xtend AI Robotics wins Phase III of USSOCOM lethal drone program
Silverback Therapeutics Announces Pricing of Initial Public Offering
December 3, 2020 10:44 PM ESTSEATTLE--(BUSINESS WIRE)-- Silverback Therapeutics, Inc. (Silverback), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced the pricing of its initial public offering of 11,500,000 shares of its common stock at a price to the public of $21.00 per share. The gross proceeds to Silverback from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $241.5 million. All of the shares are being offered by Silverback. In addition, Silverback has granted the underwriters a... More
